1. Scrip

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

 
• By Leah Samuel

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

Sunrise in Snowy Mountains
The Phase III MOUNTAIN trial missed the primary endpoint

Sage Therapeutics Inc. executives are positioning the failed MOUNTAIN trial of its antidepressant SAGE-217 as more of a molehill and suggesting that the data could still be supportive of a new drug submission to the US Food & Drug Administration.

The firm announced SAGE-217 had missed the primary endpoint in the Phase III trial in acute treatment of major depressive disorder

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D